Low-cost drug found to limit lung damage in Covid patients

Drug could have ‘major impact’ in fighting coronavirus, researchers say

Thomas Kingsley
Wednesday 19 January 2022 19:29
Comments
<p>The new treatment could also help poorer nations </p>

The new treatment could also help poorer nations

A low-cost drug is safe and effective in limiting lung damage in Covid patients, a new study has found.

Research has shown that Heparin - a widely available and affordable drug - could be used safely to treat Covid, boosting treatment options for patients suffering from severe infections.

Researchers from the Australian National University and King’s College London discovered breathing and oxygen levels improved in 70 per cent of patients after inhaling a course of Heparin.

Heparin is unique as it has anti-viral, anti-inflammatory and anti-coagulant effects which are considered relevant for the treatment of Covid.

Professor Frank van Haren, study lead in the findings, said Heparin could have a “major impact” in the fight against Covid.

“Most Covid experts agree that vaccination alone is not going to stop the pandemic. This could really assist in poorer countries where vaccination is challenging and we think it could help front line workers who could use it as a preventative measure,” Professor van Haren said.

He added: “Inhaled Heparin is a promising new possibility to provide a low-cost, safe and effective treatment for Covid that is available and affordable to low and middle-income countries around the globe.”

The researchers are coordinating further studies tracking hospital patients infected with Sars-CoV-2 in 13 countries who were given doses of inhaled Heparin.

Co-author Professor Clive Page who is co-leading study, from King’s College London, said: “Inhaled Heparin has antiviral properties which work by binding to the spike proteins the coronavirus uses to enter the cells of the body. Inhaled Heparin effectively stops the virus infecting cells in the lungs and could also stop people from getting the virus from others.

“It also works as an anti-inflammatory drug - the medicine has the ability to calm everything down when the body is mounting an exaggerated response to the virus. We already know heparin can reduce lung damage caused by this inflammation and the immune response overdrive that we see in other lung diseases which could provide benefit to patients hospitalised with Covid.”

He added: “There is no other drug that has these three different effects - anti-viral, anti-inflammatory and anti-coagulant.”

Patients with severe Covid develop blood clots in the lungs which can be lethal. Blood thinners, such as Heparin, can prevent such clots from forming.

Because the drug has antiviral properties and calms the immune system, it can be used at different stages of treatment. Indeed, treated patients included in the studies were not uniform in their Covid disease severity, which suggests inhaled Heparin is safe and effective to use across the spectrum of Covid disease.

Heparin could join a string of new treatments that will be used in the UK to treat the virus. Molnupiravir, a “game-changing” antiviral drug that significantly reduces the risk of hospitalisation and death from Covid was approved for use by the UK’s medicines regulator in November while GSK’s Xevudy (sotrovimab) was also approved in December.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in